Chemicals
Compare Stocks
4 / 10Stock Comparison
ORGN vs LIN vs EMN vs CE
Revenue, margins, valuation, and 5-year total return — side by side.
Chemicals - Specialty
Chemicals - Specialty
Chemicals
ORGN vs LIN vs EMN vs CE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Chemicals | Chemicals - Specialty | Chemicals - Specialty | Chemicals |
| Market Cap | $211M | $228.85B | $8.43B | $6.54B |
| Revenue (TTM) | $25M | $34.66B | $8.64B | $9.49B |
| Net Income (TTM) | $-69M | $7.13B | $399M | $-1.02B |
| Gross Margin | 1.8% | 46.0% | 19.8% | 20.1% |
| Operating Margin | -321.3% | 28.8% | 9.4% | -7.4% |
| Forward P/E | — | 27.7x | 12.5x | 10.4x |
| Total Debt | $10M | $26.99B | $5.08B | $12.93B |
| Cash & Equiv. | $56M | $5.06B | $566M | $1.26B |
ORGN vs LIN vs EMN vs CE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| Origin Materials, I… (ORGN) | 100 | 0.5 | -99.5% |
| Linde plc (LIN) | 100 | 207.4 | +107.4% |
| Eastman Chemical Co… (EMN) | 100 | 94.3 | -5.7% |
| Celanese Corporation (CE) | 100 | 54.3 | -45.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ORGN vs LIN vs EMN vs CE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ORGN is the clearest fit if your priority is growth.
- 8.6% revenue growth vs CE's -7.2%
LIN carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 3.0%, EPS growth 7.1%, 3Y rev CAGR 0.6%
- 375.2% 10Y total return vs EMN's 35.4%
- Lower volatility, beta 0.24, Low D/E 67.9%, current ratio 0.88x
- PEG 1.09 vs EMN's 3.89
EMN is the clearest fit if your priority is income & stability.
- Dividend streak 12 yrs, beta 1.36, yield 4.5%
- 4.5% yield, 12-year raise streak, vs LIN's 1.2%, (1 stock pays no dividend)
CE is the #2 pick in this set and the best alternative if value and momentum is your priority.
- Lower P/E (10.4x vs 12.5x)
- +20.8% vs ORGN's -92.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.6% revenue growth vs CE's -7.2% | |
| Value | Lower P/E (10.4x vs 12.5x) | |
| Quality / Margins | 20.6% margin vs ORGN's -275.0% | |
| Stability / Safety | Beta 0.24 vs ORGN's 1.68 | |
| Dividends | 4.5% yield, 12-year raise streak, vs LIN's 1.2%, (1 stock pays no dividend) | |
| Momentum (1Y) | +20.8% vs ORGN's -92.8% | |
| Efficiency (ROA) | 8.3% ROA vs ORGN's -19.7%, ROIC 11.3% vs -19.6% |
ORGN vs LIN vs EMN vs CE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ORGN vs LIN vs EMN vs CE — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
LIN leads in 4 of 6 categories
CE leads 1 • EMN leads 1 • ORGN leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
LIN leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
LIN is the larger business by revenue, generating $34.7B annually — 1379.5x ORGN's $25M. LIN is the more profitable business, keeping 20.6% of every revenue dollar as net income compared to ORGN's -2.8%. On growth, LIN holds the edge at +8.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $25M | $34.7B | $8.6B | $9.5B |
| EBITDAEarnings before interest/tax | -$70M | $12.1B | $1.2B | $58M |
| Net IncomeAfter-tax profit | -$69M | $7.1B | $399M | -$1.0B |
| Free Cash FlowCash after capex | -$55M | $5.1B | $498M | $944M |
| Gross MarginGross profit ÷ Revenue | +1.8% | +46.0% | +19.8% | +20.1% |
| Operating MarginEBIT ÷ Revenue | -3.2% | +28.8% | +9.4% | -7.4% |
| Net MarginNet income ÷ Revenue | -2.8% | +20.6% | +4.6% | -10.8% |
| FCF MarginFCF ÷ Revenue | -2.2% | +14.7% | +5.8% | +9.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -43.2% | +8.2% | -4.9% | -2.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +57.7% | +13.4% | -40.8% | +3.1% |
Valuation Metrics
CE leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 18.0x trailing earnings, EMN trades at a 47% valuation discount to LIN's 33.8x P/E. Adjusting for growth (PEG ratio), LIN offers better value at 1.33x vs EMN's 5.59x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $211M | $228.8B | $8.4B | $6.5B |
| Enterprise ValueMkt cap + debt − cash | $164M | $250.8B | $12.9B | $18.2B |
| Trailing P/EPrice ÷ TTM EPS | -2.45x | 33.85x | 17.97x | -5.49x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 27.67x | 12.50x | 10.45x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.33x | 5.59x | — |
| EV / EBITDAEnterprise value multiple | — | 19.75x | 8.96x | 12.06x |
| Price / SalesMarket cap ÷ Revenue | 6.74x | 6.73x | 0.96x | 0.68x |
| Price / BookPrice ÷ Book value/share | 0.60x | 5.82x | 1.41x | 1.43x |
| Price / FCFMarket cap ÷ FCF | — | 44.97x | 19.87x | 8.14x |
Profitability & Efficiency
LIN leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
LIN delivers a 17.8% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-22 for ORGN. ORGN carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to CE's 2.89x. On the Piotroski fundamental quality scale (0–9), LIN scores 6/9 vs ORGN's 2/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -21.9% | +17.8% | +6.7% | -21.5% |
| ROA (TTM)Return on assets | -19.7% | +8.3% | +2.6% | -4.6% |
| ROICReturn on invested capital | -19.6% | +11.3% | +6.7% | +3.4% |
| ROCEReturn on capital employed | -20.8% | +13.0% | +7.5% | +4.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.03x | 0.68x | 0.84x | 2.89x |
| Net DebtTotal debt minus cash | -$47M | $21.9B | $4.5B | $11.7B |
| Cash & Equiv.Liquid assets | $56M | $5.1B | $566M | $1.3B |
| Total DebtShort + long-term debt | $10M | $27.0B | $5.1B | $12.9B |
| Interest CoverageEBIT ÷ Interest expense | -417.10x | 34.52x | 2.22x | -0.57x |
Total Returns (Dividends Reinvested)
LIN leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LIN five years ago would be worth $17,394 today (with dividends reinvested), compared to $48 for ORGN. Over the past 12 months, CE leads with a +20.8% total return vs ORGN's -92.8%. The 3-year compound annual growth rate (CAGR) favors LIN at 11.8% vs ORGN's -77.7% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -79.9% | +15.5% | +15.8% | +38.7% |
| 1-Year ReturnPast 12 months | -92.8% | +11.2% | +2.3% | +20.8% |
| 3-Year ReturnCumulative with dividends | -98.9% | +39.7% | +3.4% | -40.8% |
| 5-Year ReturnCumulative with dividends | -99.5% | +73.9% | -28.4% | -59.5% |
| 10-Year ReturnCumulative with dividends | -99.5% | +375.2% | +35.4% | +13.3% |
| CAGR (3Y)Annualised 3-year return | -77.7% | +11.8% | +1.1% | -16.0% |
Risk & Volatility
LIN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LIN is the less volatile stock with a 0.24 beta — it tends to amplify market swings less than ORGN's 1.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIN currently trades 94.7% from its 52-week high vs ORGN's 5.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.68x | 0.24x | 1.36x | 1.11x |
| 52-Week HighHighest price in past year | $28.49 | $521.28 | $84.18 | $70.70 |
| 52-Week LowLowest price in past year | $0.20 | $387.78 | $56.11 | $35.13 |
| % of 52W HighCurrent price vs 52-week peak | +5.0% | +94.7% | +87.5% | +82.6% |
| RSI (14)Momentum oscillator 0–100 | 30.7 | 51.7 | 56.9 | 45.0 |
| Avg Volume (50D)Average daily shares traded | 161K | 2.3M | 1.5M | 2.4M |
Analyst Outlook
EMN leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ORGN as "Buy", LIN as "Buy", EMN as "Buy", CE as "Hold". Consensus price targets imply 6238.0% upside for ORGN (target: $90) vs 4.9% for EMN (target: $77). For income investors, EMN offers the higher dividend yield at 4.47% vs CE's 0.20%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $90.00 | $539.71 | $77.29 | $65.40 |
| # AnalystsCovering analysts | 6 | 28 | 35 | 37 |
| Dividend YieldAnnual dividend ÷ price | — | +1.2% | +4.5% | +0.2% |
| Dividend StreakConsecutive years of raises | — | 6 | 12 | 0 |
| Dividend / ShareAnnual DPS | — | $6.00 | $3.30 | $0.12 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.0% | +1.2% | 0.0% |
LIN leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CE leads in 1 (Valuation Metrics).
ORGN vs LIN vs EMN vs CE: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ORGN or LIN or EMN or CE a better buy right now?
For growth investors, Origin Materials, Inc.
(ORGN) is the stronger pick with 8. 6% revenue growth year-over-year, versus -7. 2% for Celanese Corporation (CE). Eastman Chemical Company (EMN) offers the better valuation at 18. 0x trailing P/E (12. 5x forward), making it the more compelling value choice. Analysts rate Origin Materials, Inc. (ORGN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ORGN or LIN or EMN or CE?
On trailing P/E, Eastman Chemical Company (EMN) is the cheapest at 18.
0x versus Linde plc at 33. 8x. On forward P/E, Celanese Corporation is actually cheaper at 10. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Linde plc wins at 1. 09x versus Eastman Chemical Company's 3. 89x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — ORGN or LIN or EMN or CE?
Over the past 5 years, Linde plc (LIN) delivered a total return of +73.
9%, compared to -99. 5% for Origin Materials, Inc. (ORGN). Over 10 years, the gap is even starker: LIN returned +375. 2% versus ORGN's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ORGN or LIN or EMN or CE?
By beta (market sensitivity over 5 years), Linde plc (LIN) is the lower-risk stock at 0.
24β versus Origin Materials, Inc. 's 1. 68β — meaning ORGN is approximately 600% more volatile than LIN relative to the S&P 500. On balance sheet safety, Origin Materials, Inc. (ORGN) carries a lower debt/equity ratio of 3% versus 3% for Celanese Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — ORGN or LIN or EMN or CE?
By revenue growth (latest reported year), Origin Materials, Inc.
(ORGN) is pulling ahead at 8. 6% versus -7. 2% for Celanese Corporation (CE). On earnings-per-share growth, the picture is similar: Celanese Corporation grew EPS 23. 6% year-over-year, compared to -441. 2% for Origin Materials, Inc.. Over a 3-year CAGR, LIN leads at 0. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ORGN or LIN or EMN or CE?
Linde plc (LIN) is the more profitable company, earning 20.
3% net margin versus -267. 6% for Origin Materials, Inc. — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LIN leads at 26. 3% versus -271. 3% for ORGN. At the gross margin level — before operating expenses — LIN leads at 43. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ORGN or LIN or EMN or CE more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Linde plc (LIN) is the more undervalued stock at a PEG of 1. 09x versus Eastman Chemical Company's 3. 89x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Celanese Corporation (CE) trades at 10. 4x forward P/E versus 27. 7x for Linde plc — 17. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ORGN: 6238. 0% to $90. 00.
08Which pays a better dividend — ORGN or LIN or EMN or CE?
In this comparison, EMN (4.
5% yield), LIN (1. 2% yield), CE (0. 2% yield) pay a dividend. ORGN does not pay a meaningful dividend and should not be held primarily for income.
09Is ORGN or LIN or EMN or CE better for a retirement portfolio?
For long-horizon retirement investors, Linde plc (LIN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
24), 1. 2% yield, +375. 2% 10Y return). Origin Materials, Inc. (ORGN) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LIN: +375. 2%, ORGN: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ORGN and LIN and EMN and CE?
Both stocks operate in the Basic Materials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ORGN is a small-cap quality compounder stock; LIN is a large-cap quality compounder stock; EMN is a small-cap deep-value stock; CE is a small-cap quality compounder stock. LIN, EMN pay a dividend while ORGN, CE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.